Abu-Freha Naim, Michael Tal, Poupko Liat, Estis-Deaton Asia, Aasla Muhammad, Abu-Freha Omar, Etzion Ohad, Nesher Lior
The Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer-Sheva 84105, Israel.
The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
J Clin Med. 2021 Dec 31;11(1):227. doi: 10.3390/jcm11010227.
(1) Background: Spontaneous bacterial peritonitis (SBP) is a feared complication of liver cirrhosis. We investigated the prevalence of SBP, positive ascitic fluid cultures, and risk factors for mortality. (2) Methods: A retrospective analysis of all patients with cirrhosis hospitalized or in follow-up in a single center between 1996 and 2020. The clinical data, long-term complications, and mortality of SBP patients were compared with those of non-SBP patients. Ascitic fluid positive culture was compared with those without growth. (3) Results: We included 1035 cirrhotic patients, of which 173 (16.7%) developed SBP. Ascitic fluid culture growth was found in 47.4% of the SBP cases, with Escherichia coli bacteria detected in 38%, 24.4% grew ESBL-producing bacteria, and 14.5% displayed multidrug resistance. In a Cox regression model, SBP, male sex, prolonged INR at diagnosis, and hepatocellular carcinoma were found to be risk factors for mortality in cirrhotic patients. The long-term all-cause mortality was 60% in non-SBP and 90% in SBP patients. (4) Conclusions: Only a minority of cirrhotic patients developed SBP, 47.4% of which had positive ascitic fluid cultures with high antibiotic resistance. Growth of ESBL and multidrug resistant organisms is becoming more frequent in the clinical setting, reaching SBP mortality of 90%.
(1) 背景:自发性细菌性腹膜炎(SBP)是肝硬化令人恐惧的并发症。我们调查了SBP的患病率、腹水培养阳性情况以及死亡危险因素。(2) 方法:对1996年至2020年在单一中心住院或接受随访的所有肝硬化患者进行回顾性分析。将SBP患者的临床数据、长期并发症和死亡率与非SBP患者进行比较。将腹水培养阳性结果与无细菌生长的结果进行比较。(3) 结果:我们纳入了1035例肝硬化患者,其中173例(16.7%)发生了SBP。在47.4%的SBP病例中发现腹水培养有细菌生长,其中检测到大肠杆菌的占38%,产超广谱β-内酰胺酶(ESBL)细菌生长的占24.4%,显示多重耐药的占14.5%。在Cox回归模型中,SBP、男性、诊断时INR延长以及肝细胞癌被发现是肝硬化患者死亡的危险因素。非SBP患者的长期全因死亡率为60%,SBP患者为90%。(4) 结论:只有少数肝硬化患者发生SBP,其中47.4%的患者腹水培养阳性且抗生素耐药性高。ESBL和多重耐药菌在临床环境中越来越常见,SBP死亡率达90%。